Labs / ADME, DMPK & toxicology
Ablevia biotech
Vienna, Austria · ablevia.com
Ablevia biotech develops a selective antibody removal pre-treatment platform for advanced biologics and delivery systems. It works with partners developing therapies affected by anti-drug or anti-vector antibodies, including PEGylated drugs and PEGylated LNP-based RNA and DNA delivery, from Vienna, Austria.
They take quote requests by email.
What they offer
Selective antibody removal pre-treatment platform
An injectable pre-treatment platform based on Selective Antibody Depletion Compounds (SADCs) that removes circulating anti-drug and anti-vector antibodies before dosing.
Anti-PEG antibody depletion
A lead SADC program that rapidly removes anti-PEG antibodies to restore the performance of PEGylated drugs and PEGylated LNP delivery.
Selective antibody depletion for advanced therapeutics
Development of next-generation SADCs intended to target protein-directed anti-drug and anti-vector antibodies for broader therapeutic use.
ADA epitope profiling support
Deep profiling of ADA epitopes to guide the design and expansion of selective antibody removal programs.
What they work on
- Modalities
- Antibody, LNP / formulation
- Assays and studies
- ADA epitope profiling
- Therapeutic areas
- oncology, rare diseases, metabolic diseases
- Sites
- Vienna, Austria
Similar labs. Transcenta Holding, Aurigene Pharmaceutical Services, Bioklone Biotech Private Limited, Bioneeds
Found in a contract services directory. Listing built from ablevia.com. Work here? Claim this listing.